Natalizumab Re-Initiation of Dosing

PHASE3CompletedINTERVENTIONAL
Enrollment

404

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

February 29, 2008

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BIOLOGICAL

BG00002 (natalizumab)

Trial Locations (63)

10003

Research Site, New York

10019

Research Site, Great Neck

10305

Research Site, Staten Island

10319

Research Site, New York

12208

Research Site, Albany

13202

Research Site, Syracuse

14203

Research Site, Buffalo

15212

Research Site, Pittsburgh

15213

Research Site, Pittsburgh

18103

Research Site, Allentown

19104

Research Site, Philadelphia

19146

Research Site, Philadelphia

20007

Research Site, Washington D.C.

21201

Research Site, Baltimore

22903

Research Site, Charlottesville

27607

Research Site, Raleigh

28207

Research Site, Charlotte

30327

Research Site, Atlanta

32751

Research Site, Maitland

33060

Research Site, Pompano Beach

33136

Research Site, Miami

35233

Research Site, Birmingham

37215

Research Site, Nashville

38163

Research Site, Memphis

44195

Research Site, Cleveland

45219

Research Site, Cincinnati

48334

Research Site, Farmington Hills

48824

Research Site, East Lansing

50314

Research Site, Des Moines

53215

Research Site, Milwaukee

58103

Research Site, Fargo

60007

Research Site, Arlington

60062

Research Site, Northbrook

60612

Research Site, Chicago

60637

Research Site, Chicago

66160

Research Site, Kansas City

72205

Research Site, Little Rock

75214

Research Site, Dallas

78681

Research Site, Round Rock

80919

Research Site, Colorado Springs

85006

Research Site, Phoenix

85259

Research Site, Scottsdale

87131

Research Site, Albuquerque

90033

Research Site, Los Angeles

94063

Research Site, Redwood City

94117

Research Site, San Francisco

94705

Research Site, Berkeley

95817

Research Site, Sacramento

97225

Research Site, Portland

06510

Research Site, New Haven

01655

Research Site, Worcester

07666

Research Site, Teaneck

05401

Research Site, Burlington

V6T2B5

Research Site, Vancouver

B3H1V7

Research Site, Halifax

K7L2V7

Research Site, Kingston

N6A5A5

Research Site, London

M4N 3M5

Research Center, New York

K2G6E2

Research Site, Ottawa

M5B1W8

Research Site, Toronto

J8Y1W7

Research Site, Gatineau

J4V2H1

Research Site, Greenfield Park

H3A2B4

Research Site, Montreal

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Elan Pharmaceuticals

INDUSTRY

lead

Biogen

INDUSTRY